Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2025
|
| In: |
ESMO open
Year: 2025, Jahrgang: 10, Heft: 5, Pages: 1 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2025.105063 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.esmoop.2025.105063 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702925009329 
|
| Verfasserangaben: | H.C. Puhr, E.C. Winkler & M. Preusser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1941608957 | ||
| 003 | DE-627 | ||
| 005 | 20251120161804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251119s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2025.105063 |2 doi | |
| 035 | |a (DE-627)1941608957 | ||
| 035 | |a (DE-599)KXP1941608957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Puhr, Hannah Christina |d 1994- |e VerfasserIn |0 (DE-588)1372318798 |0 (DE-627)193173917X |4 aut | |
| 245 | 1 | 0 | |a Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |c H.C. Puhr, E.C. Winkler & M. Preusser |
| 264 | 1 | |c May 2025 | |
| 300 | |a 1 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 15. April 2025 | ||
| 500 | |a Gesehen am 19.11.2025 | ||
| 700 | 1 | |a Winkler, Eva C. |d 1971- |e VerfasserIn |0 (DE-588)1055853065 |0 (DE-627)792734823 |0 (DE-576)411905384 |4 aut | |
| 700 | 1 | |a Preusser, Matthias |d 1976- |e VerfasserIn |0 (DE-588)1156333008 |0 (DE-627)1019103949 |0 (DE-576)502110627 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 10(2025), 5 vom: Mai, Artikel-ID 105063, Seite 1 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |
| 773 | 1 | 8 | |g volume:10 |g year:2025 |g number:5 |g month:05 |g elocationid:105063 |g pages:1 |g extent:1 |a Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |
| 787 | 0 | 8 | |i Ergänzung zu |a Lilienfeld-Toal, Marie von, 1971 - |t Letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022 |d 2025 |w (DE-627)1941726933 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2025.105063 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702925009329 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251119 | ||
| 993 | |a Editorial | ||
| 994 | |a 2025 | ||
| 998 | |g 1055853065 |a Winkler, Eva C. |m 1055853065:Winkler, Eva C. |d 910000 |d 912900 |e 910000PW1055853065 |e 912900PW1055853065 |k 0/910000/ |k 1/910000/912900/ |p 2 | ||
| 999 | |a KXP-PPN1941608957 |e 4808679116 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022","title":"Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022"}],"person":[{"given":"Hannah Christina","display":"Puhr, Hannah Christina","family":"Puhr","role":"aut"},{"given":"Eva C.","display":"Winkler, Eva C.","family":"Winkler","role":"aut"},{"role":"aut","display":"Preusser, Matthias","given":"Matthias","family":"Preusser"}],"recId":"1941608957","origin":[{"dateIssuedDisp":"May 2025","dateIssuedKey":"2025"}],"name":{"displayForm":["H.C. Puhr, E.C. Winkler & M. Preusser"]},"relHost":[{"recId":"84705344X","disp":"Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022ESMO open","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2016 -"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"origin":[{"dateIssuedDisp":"2016-","publisher":"Elsevier ; BMJ","publisherPlace":"[London] ; London","dateIssuedKey":"2016"}],"name":{"displayForm":["European Society for Medical Oncology"]},"title":[{"title":"ESMO open","subtitle":"cancer horizons","title_sort":"ESMO open"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"10","text":"10(2025), 5 vom: Mai, Artikel-ID 105063, Seite 1","year":"2025","pages":"1","extent":"1","issue":"5"},"id":{"issn":["2059-7029"],"zdb":["2844985-X"],"eki":["84705344X"]},"note":["Gesehen am 13.06.24"]}],"note":["Online veröffentlicht: 15. April 2025","Gesehen am 19.11.2025"],"physDesc":[{"extent":"1 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1941608957"],"doi":["10.1016/j.esmoop.2025.105063"]}} | ||
| SRT | |a PUHRHANNAHRESPONSETO2025 | ||